Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

Despite the availability of a lot of effective disease-modifying drugs, multiple sclerosis (MS) (in particular the progressive forms) still represents an important unmet medical need, because of issues in terms of effectiveness, duration of response, safety, and patient compliance. An increasing bod...

Descripción completa

Detalles Bibliográficos
Autores principales: Brancati, Serena, Gozzo, Lucia, Longo, Laura, Vitale, Daniela Cristina, Drago, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290177/
https://www.ncbi.nlm.nih.gov/pubmed/34295328
http://dx.doi.org/10.3389/fimmu.2021.661882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290177/
https://www.ncbi.nlm.nih.gov/pubmed/34295328
http://dx.doi.org/10.3389/fimmu.2021.661882

Ejemplares similares